糖皮质激素受体拮抗剂在重度抑郁症治疗中的可能应用：使用RU 486的初步结果
Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.
作者信息
Murphy B E, Filipini D, Ghadirian A M
机构信息
Department of Medicine, McGill University, Montreal, Quebec.
出版信息
J Psychiatry Neurosci. 1993 Nov;18(5):209-13.
Abstract
The rationale for the use of anti-glucocorticoids in the treatment of major depression has been reviewed. Four patients with chronic severe depression who were resistant to conventional therapies were given RU 486 (200 mg/day) for periods up to eight weeks. Substantial levels of RU 486 were achieved within the first few days, and the levels fell gradually over the week after the treatment was discontinued. In three cases, treatment was stopped before the eight weeks were completed: in one case because of the appearance of a rash, in the others because of side-effects, which, in retrospect, were likely unrelated to the drug. The mean scores on the Hamilton Rating Scale for Depression of three patients decreased. Levels of adrenocorticotrophin, dehydroepiandrosterone and cortisol rose during treatment. These preliminary results suggest that glucocorticoid antagonists may be effective in the treatment of major depression and merit further exploration.
摘要
抗糖皮质激素用于治疗重度抑郁症的理论依据已得到综述。4例对传统疗法耐药的慢性重度抑郁症患者接受了RU 486（200毫克/天）治疗，疗程长达8周。在最初几天内就达到了较高的RU 486水平，停药后一周内该水平逐渐下降。3例患者在8周疗程结束前停止治疗：1例是因为出现皮疹，其他几例是因为出现副作用，回顾起来，这些副作用可能与药物无关。3例患者的汉密尔顿抑郁量表平均得分有所下降。治疗期间促肾上腺皮质激素、脱氢表雄酮和皮质醇水平升高。这些初步结果表明，糖皮质激素拮抗剂可能对治疗重度抑郁症有效，值得进一步探索。
相似文献
1
Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.糖皮质激素受体拮抗剂在重度抑郁症治疗中的可能应用：使用RU 486的初步结果
J Psychiatry Neurosci. 1993 Nov;18(5):209-13.
2
Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.米非司酮（RU - 486）对双相情感障碍和精神分裂症患者皮质醇水平的持续影响。
J Psychiatr Res. 2008 Oct;42(12):1037-41. doi: 10.1016/j.jpsychires.2007.12.005. Epub 2008 Feb 5.
3
Antiglucocorticoid therapies in major depression: a review.
Psychoneuroendocrinology. 1997;22 Suppl 1:S125-32.
4
Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.米非司酮（RU - 486）辅助治疗双相情感障碍后神经认知功能和情绪的改善。
Neuropsychopharmacology. 2004 Aug;29(8):1538-45. doi: 10.1038/sj.npp.1300471.
5
Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.脱氢表雄酮单药治疗中年起病的重度和轻度抑郁症。
Arch Gen Psychiatry. 2005 Feb;62(2):154-62. doi: 10.1001/archpsyc.62.2.154.
6
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.甲吡酮作为重度抑郁症的辅助治疗：一项双盲安慰剂对照试验。
Arch Gen Psychiatry. 2004 Dec;61(12):1235-44. doi: 10.1001/archpsyc.61.12.1235.
7
Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.辅助使用米非司酮（RU-486）对精神分裂症神经认知功能及症状的影响。
Biol Psychiatry. 2005 Jan 15;57(2):155-61. doi: 10.1016/j.biopsych.2004.10.017.
8
Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression.皮质醇合成抑制：一种针对抑郁症临床及内分泌表现的新治疗策略。
Biol Psychiatry. 1995 Mar 15;37(6):364-8. doi: 10.1016/0006-3223(94)00137-R.
9
Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report.酮康唑抗糖皮质激素治疗难治性抑郁症：一例报告
Biol Psychiatry. 1995 Mar 1;37(5):338-40. doi: 10.1016/0006-3223(94)00245-X.
10
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.比较三甲丙咪嗪单一疗法与阿米替林和氟哌啶醇联合疗法治疗妄想性抑郁症的疗效——一项双盲多中心试验。
J Psychiatr Res. 2009 Apr;43(7):702-10. doi: 10.1016/j.jpsychires.2008.10.004. Epub 2008 Nov 26.
引用本文的文献
1
Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work.激素回路解释了为何大多数下丘脑-垂体-肾上腺（HPA）药物治疗情绪障碍无效，并预测了少数有效的药物。
Mol Syst Biol. 2025 Mar;21(3):254-273. doi: 10.1038/s44320-024-00083-0. Epub 2025 Jan 23.
2
Dynamics of ACTH and Cortisol Secretion and Implications for Disease.促肾上腺皮质激素（ACTH）和皮质醇分泌的动力学及其对疾病的影响。
Endocr Rev. 2020 Jun 1;41(3). doi: 10.1210/endrev/bnaa002.
3
Sex differences in the hypothalamic-pituitary-adrenal axis: An obstacle to antidepressant drug development?下丘脑-垂体-肾上腺轴的性别差异：抗抑郁药物研发的障碍？
Br J Pharmacol. 2019 Nov;176(21):4090-4106. doi: 10.1111/bph.14710. Epub 2019 Jun 26.
4
Resetting the Stress System with a Mifepristone Challenge.米非司酮挑战重置应激系统。
Cell Mol Neurobiol. 2019 May;39(4):503-522. doi: 10.1007/s10571-018-0614-5. Epub 2018 Sep 1.
5
HPA Axis Interactions with Behavioral Systems.下丘脑-垂体-肾上腺轴与行为系统的相互作用。
Compr Physiol. 2016 Sep 15;6(4):1897-1934. doi: 10.1002/cphy.c150042.
6
Antidepressant-Like Effects of Lindera obtusiloba Extracts on the Immobility Behavior of Rats in the Forced Swim Test.钝叶山胡椒提取物对强迫游泳试验中大鼠不动行为的抗抑郁样作用。
Molecules. 2016 Feb 27;21(3):277. doi: 10.3390/molecules21030277.
7
Antiglucocorticoids as Treatments for Depression : Rationale for Use and Therapeutic Potential.抗糖皮质激素作为抑郁症的治疗方法：使用原理及治疗潜力
CNS Drugs. 1996 May;5(5):311-20. doi: 10.2165/00023210-199605050-00001.
8
Advances in the Management of Treatment-Resistant Depression.难治性抑郁症的治疗进展
Focus (Am Psychiatr Publ). 2010 Fall;8(4):488-500. doi: 10.1176/foc.8.4.foc488.
9
Mifepristone prevents stress-induced apoptosis in newborn neurons and increases AMPA receptor expression in the dentate gyrus of C57/BL6 mice.米非司酮可预防新生神经元应激诱导的细胞凋亡，并增加 C57/BL6 小鼠齿状回 AMPA 受体的表达。
PLoS One. 2011;6(11):e28376. doi: 10.1371/journal.pone.0028376. Epub 2011 Nov 30.
10
Therapeutic options for treatment-resistant depression.治疗抵抗性抑郁症的治疗选择。
CNS Drugs. 2010 Feb;24(2):131-61. doi: 10.2165/11530280-000000000-00000.
本文引用的文献
1
A rating scale for depression.一种抑郁症评定量表。
J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56.
2
Stress down-regulates corticosterone receptors in a site-specific manner in the brain.压力以位点特异性方式下调大脑中的皮质酮受体。
Endocrinology. 1984 Jan;114(1):287-92. doi: 10.1210/endo-114-1-287.
3
The new steroid analog RU 486 inhibits glucocorticoid action in man.新型类固醇类似物RU 486可抑制人体中的糖皮质激素作用。
J Clin Endocrinol Metab. 1984 Jul;59(1):25-8. doi: 10.1210/jcem-59-1-25.
4
Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test.
Am J Psychiatry. 1985 Nov;142(11):1278-84. doi: 10.1176/ajp.142.11.1278.
5
Glucocorticoid receptors and depression.糖皮质激素受体与抑郁症。
Br Med J (Clin Res Ed). 1986 Mar 29;292(6524):859-61. doi: 10.1136/bmj.292.6524.859.
6
Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.
J Clin Endocrinol Metab. 1985 Sep;61(3):536-40. doi: 10.1210/jcem-61-3-536.
7
RU 38486: a potent antiglucocorticoid in vitro and in vivo.RU 38486：一种在体外和体内均有效的抗糖皮质激素。
J Steroid Biochem. 1985 Sep;23(3):247-51. doi: 10.1016/0022-4731(85)90401-7.
8
Treatment of major depression with steroid suppressive drugs.使用类固醇抑制药物治疗重度抑郁症。
J Steroid Biochem Mol Biol. 1991 Aug;39(2):239-44. doi: 10.1016/0960-0760(91)90069-h.
9
Response to steroid suppression in major depression resistant to antidepressant therapy.
J Clin Psychopharmacol. 1991 Apr;11(2):121-6.
10
Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain.抗抑郁药及其他中枢作用药物可调节大鼠脑中糖皮质激素受体信使核糖核酸的水平。
Psychoneuroendocrinology. 1991;16(6):505-15. doi: 10.1016/0306-4530(91)90034-q.
Zotero 插件